Login
If you are a Larta client with an ongoing program, log-in here:

 
 
For technical support please email mtecson@larta.org

To retrieve login information click here

Equipping Global Entrepreneurs

Bionext Produtos Biotecnologicos, Ltda.

Bionext, based in Brazil, specializes in producing Microbial Cellulose (MC), a versatile biomaterial with broad applications in industries as diverse as food, electronics, and paper products. Their first product is a highly-effective wound-dressing material which improves the healing process for burns and for chronic and acute wounds. Other important offerings involve MC membranes for internal use and biostents coated with biosynthetic cellulose, which is 100% biocompatible and is effective in controlling restenosis following coronary angioplasty.

Theralase Technologies

Theralase, based in Canada, designs, manufactures and distributes patented, super-pulsed laser and light-based technology systems used in a wide range of therapeutic clinical applications. The Theralase technology platform has been proven clinically effective in non-invasive pain management and clinical therapy, including hundreds of different neural muscular skeletal conditions such as sports injuries, repetitive strain injuries and arthritis. Theralase has patented technologies currently under research and development focused on two main areas: increased clinical efficacies in therapeutic treatment and the destruction of cancer, viruses, bacteria and fat cells through the light activation of specially designed photodynamic compounds.

Innovent Medical Solutions, Ltd

Innovent Medical Solutions is a development stage company that was founded in 2003 to commercialize a new airway clearance technology first invented at Alyn Rehabilitation Hospital for use with its respiratory patients. The device, a patented combination of a suction unit and a disposable valve, offers a revolutionary approach to preventing a major healthcare problem in the ICU: Ventilator Associated Pneumonia (VAP).

"The (Larta) seminar had a profound impact on the fundraising strategy and methodology of our company ... we closed a $1.2M series A investment round, and we will be commencing trials in Israel in 9 months time. Positive momentum seems to build on itself, and several more angels, and industry sources, have contacted us to express interest."

Eliezer Be'eri,
Founder and CSO, Innovent Medical Solutions Ltd.